CAPLIN POINT LABORATORIES LTD.
NSE : CAPLIPOINTBSE : 524742ISIN
CODE : INE475E01026Industry : Pharmaceuticals & DrugsHouse
: Private
BSE1318.45-20.05 (-1.5 % )
PREV CLOSE (Rs.) 1338.50
OPEN PRICE (Rs.) 1328.40
BID PRICE (QTY) 1315.00 (3 )
OFFER PRICE (QTY) 1315.75 (5 )
VOLUME 945
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE1325.75 -15.55 (-1.16 % )
PREV CLOSE(Rs.) 1341.30
OPEN PRICE (Rs.) 1340.05
BID PRICE (QTY) 1325.75 (24 )
OFFER PRICE (QTY) 1327.55 (5 )
VOLUME 8289
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 06-May-2024 | Caplin Point gets Colombia's INVIMA approval for Softgel Capsules division | <p style="text-align: justify;">Caplin Point Laboratories has received Colombia's INVIMA approval for its Softgel Capsules division at Puducherry. The site inspection of Unit-1 was completed on May 3 and found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).</p><p style="text-align: justify;">The Unit currently caters to Emerging Markets of Latin America and Africa with a variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories, Liquid Orals, Topicals and Injectables.</p><p style="text-align: justify;">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.</p><div style="text-align: justify;"><br></div> |
| 06-May-2024 | Caplin Point moves up on getting Colombia's INVIMA approval for Softgel Capsules division | <p style="text-align: justify;">Caplin Point Laboratories is currently trading at Rs. 1301.70, up by 2.90 points or 0.22% from its previous closing of Rs. 1298.80 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 1300.00 and has touched a high and low of Rs. 1321.00 and Rs. 1277.85 respectively. So far 7824 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1617.80 on 19-Feb-2024 and a 52 week low of Rs. 673.10 on 05-May-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 1370.15 and Rs. 1277.85 respectively. The current market cap of the company is Rs. 9836.35 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 70.62%, while Institutions and Non-Institutions held 4.43% and 24.95% respectively.</p><p style="text-align: justify;">Caplin Point Laboratories has received Colombia's INVIMA approval for its Softgel Capsules division at Puducherry. The site inspection of Unit-1 was completed on May 3 and found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).</p><p style="text-align: justify;">The Unit currently caters to Emerging Markets of Latin America and Africa with a variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories, Liquid Orals, Topicals and Injectables.</p><p style="text-align: justify;">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.</p> |
| 16-Apr-2024 | Caplin Point Laboratories' arm gets final approval from USFDA for Ofloxacin Ophthalmic Solution | <p style="text-align: justify;">Caplin Point Laboratories' subsidiary company -- Caplin Steriles (Caplin) has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Ophthalmic Solution USP 0.3% (eye drops), a generic therapeutic equivalent version of (RLD), OCUFLOX Ophthalmic Solution of Allergan Inc. </p><p style="text-align: justify;">Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers. According to IQVIA (IMS Health), Ofloxacin Ophthalmic Solution USP 0.3% had US sales of around $52 million for the 12- month period ending December 2023.</p><p style="text-align: justify;">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.</p><div style="text-align: justify;"><br></div> |
| 16-Apr-2024 | Caplin Point Laboratories informs about press release | <p style="text-align: justify;">Caplin Point Laboratories has informed that it enclosed press release regarding grant of final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Ofloxacin Ophthalmic Solution 0.3% (eye drops), to its Subsidiary Caplin Steriles.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 28-Mar-2024 | Caplin Point Laboratories' arm gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution | <p style="text-align: justify;">Caplin Point Laboratories' subsidiary -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac tromethamine Ophthalmic Solution 0.5% (eye drops), a generic therapeutic equivalent version of (RLD), ACULAR Ophthalmic Solution of Allergan Inc.</p><p style="text-align: justify;">Ketorolac tromethamine Ophthalmic Solution 0.5% is a nonsteroidal, anti- inflammatory indicated for the treatment of inflammation following cataract surgery and for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. According to IQVIATM (IMS Health), Ketorolac tromethamine Ophthalmic Solution 0.5% had US sales of around $36 million for the 12-month period ending December 2023.</p><p style="text-align: justify;">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.</p><div style="text-align: justify;"><br></div> |
| 28-Mar-2024 | Caplin Point Laboratories gains as its arm gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution | <p style="text-align: justify;">Caplin Point Laboratories is currently trading at Rs. 1283.80, up by 23.85 points or 1.89 % from its previous closing of Rs. 1259.95 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 1289.90 and has touched a high and low of Rs. 1302.35 and Rs. 1259.45 respectively. So far 4701 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1617.80 on 19-Feb-2024 and a 52 week low of Rs. 575.00 on 29-Mar-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 1302.35 and Rs. 1240.00 respectively. The current market cap of the company is Rs. 9648.78 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 70.62 % while Institutions and Non-Institutions held 3.26 % and 26.10 % respectively.</p><p style="text-align: justify;">Caplin Point Laboratories' subsidiary -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac tromethamine Ophthalmic Solution 0.5% (eye drops), a generic therapeutic equivalent version of (RLD), ACULAR Ophthalmic Solution of Allergan Inc.</p><p style="text-align: justify;">Ketorolac tromethamine Ophthalmic Solution 0.5% is a nonsteroidal, anti- inflammatory indicated for the treatment of inflammation following cataract surgery and for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. According to IQVIATM (IMS Health), Ketorolac tromethamine Ophthalmic Solution 0.5% had US sales of around $36 million for the 12-month period ending December 2023.</p><p style="text-align: justify;">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.</p> |
| 28-Mar-2024 | Caplin Point Laboratories informs about press release | <div style="text-align: justify;">Caplin Point Laboratories has attached a Press Release regarding grant of final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Ketorolac tromethamine Ophthalmic Solution 0.5% (eye drops), to its Subsidiary Caplin Steriles.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 27-Mar-2024 | Caplin Point Laboratories' arm completes new Oncology facility in Kakkalur | <p style="text-align: justify;">Caplin Point Laboratories' wholly owned subsidiary -- Caplin One Labs has completed its state-of-the-art Oncology facility at Kakkalur, near Chennai, and immediate commencement of operations. The total investment commitment for this facility is Rs 150 crore, funded entirely from internal accruals. To start with, the unit will focus on manufacturing a range of Oral Solid Dosage Oncology products, with the Injectable division to commence operations in the next few months. The company plans to expand the portfolio to over 50 oncology products progressively. </p><p style="text-align: justify;">The facility will manufacture tablets (both coated & uncoated), capsules, and injections, catering to the growing demand for high-quality pharmaceuticals in the oncology segment. Initially, these oncology products will be targeted at Latin American countries, leveraging Caplin Group's established presence in these markets. </p><p style="text-align: justify;">In the medium term, Caplin One Labs aims to launch these oncology products in regulated markets such as the US, EU, Mexico, and others. The facility's compliance with USFDA standards from the outset is expected to streamline the approval process, ensuring swift market entry and availability of these critical treatments to patients worldwide. Caplin Group remains dedicated to advancing healthcare solutions, improving patient outcomes, and making a positive impact on communities globally.</p><p style="text-align: justify;">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.</p> |
| 27-Mar-2024 | Caplin Point Laboratories informs about press release | <p style="text-align: justify;">Caplin Point Laboratories has informed that it attached a Press Release regarding completion of state-of-the-art Oncology facility at Kakkalur, near Chennai, and commencement of operations by Caplin One Labs (Formerly Known as Caplin Onco), the wholly-owned subsidiary of the company. </p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 27-Feb-2024 | Caplin Point Laboratories informs about loss of share certificate | <p style="text-align: justify;">Caplin Point Laboratories has informed that the share certificates have been reported as lost by the shareholders of the Company and the shareholder(s) has requested the Company to issue duplicate share certificates in lieu thereof. The Company has initiated necessary formalities in this regard. Details of the shareholders and share certificate are enclosed. </p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
